241 related articles for article (PubMed ID: 30368448)
1. Real-world effectiveness evaluation of budesonide/formoterol Spiromax for the management of asthma and chronic obstructive pulmonary disease in the UK.
Voorham J; Roche N; Benhaddi H; van der Tol M; Carter V; van Boven JFM; Bjermer L; Miravitlles M; Price DB
BMJ Open; 2018 Oct; 8(10):e022051. PubMed ID: 30368448
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of inhaler technique and achievement and maintenance of mastery of budesonide/formoterol Spiromax® compared with budesonide/formoterol Turbuhaler® in adult patients with asthma: the Easy Low Instruction Over Time (ELIOT) study.
Price DB; Thomas V; Richard Dekhuijzen PN; Bosnic-Anticevich S; Roche N; Lavorini F; Raju P; Freeman D; Nicholls C; Small IR; Sims E; Safioti G; Canvin J; Chrystyn H
BMC Pulm Med; 2018 Jun; 18(1):107. PubMed ID: 29954359
[TBL] [Abstract][Full Text] [Related]
3. Budesonide + formoterol delivered via Spiromax
Lewis A; Torvinen S; Dekhuijzen PNR; Chrystyn H; Melani A; Zöllner Y; Kolbe K; Watson AT; Blackney M; Plich A
Respir Med; 2017 Aug; 129():179-188. PubMed ID: 28732829
[TBL] [Abstract][Full Text] [Related]
4. Onset of action of budesonide/formoterol Spiromax(®) compared with budesonide/formoterol Turbuhaler(®) in patients with COPD.
Cazzola M; Ora J; Di Paolo A; Puxeddu E; Calzetta L; Rogliani P
Pulm Pharmacol Ther; 2016 Aug; 39():48-53. PubMed ID: 27344046
[TBL] [Abstract][Full Text] [Related]
5. A randomized, double-blinded, double-dummy efficacy and safety study of budesonide-formoterol Spiromax® compared to budesonide-formoterol Turbuhaler® in adults and adolescents with persistent asthma.
Virchow JC; Rodriguez-Roisin R; Papi A; Shah TP; Gopalan G
BMC Pulm Med; 2016 Mar; 16():42. PubMed ID: 26987997
[TBL] [Abstract][Full Text] [Related]
6. Patient Satisfaction and Clinical Outcomes with Budesonide plus Formoterol Spiromax for Asthma and Chronic Obstructive Pulmonary Disease: A Real-World, Observational Trial.
Gillissen A; Gessner C; Hechenbichler K; Herth FJF; Juenemann R; Kanniess F; Kardos P; Lommatzsch M; Schneidereit R; Windisch W
Respiration; 2019; 97(4):292-301. PubMed ID: 30391944
[TBL] [Abstract][Full Text] [Related]
7. Inhalation characteristics of asthma patients, COPD patients and healthy volunteers with the Spiromax® and Turbuhaler® devices: a randomised, cross-over study.
Azouz W; Chetcuti P; Hosker H; Saralaya D; Chrystyn H
BMC Pulm Med; 2015 May; 15():47. PubMed ID: 25927483
[TBL] [Abstract][Full Text] [Related]
8. DuoResp
van der Palen J; Cerveri I; Roche N; Singh D; Plaza V; Gonzalez C; Patino O; Scheepstra I; Safioti G; Backer V
J Asthma; 2020 Oct; 57(10):1110-1118. PubMed ID: 31293211
[No Abstract] [Full Text] [Related]
9. A Comparison of Short-Term Growth During Treatment with Two Dry Powder Combinations of Inhaled Corticosteroids and Long-Acting β₂-Agonists.
Wolthers OD; Shah T
J Aerosol Med Pulm Drug Deliv; 2015 Jun; 28(3):182-8. PubMed ID: 25166221
[TBL] [Abstract][Full Text] [Related]
10. Real-life budesonide and formoterol dose emission from the medium and high strength fixed dosed combinations in a Spiromax® dry powder inhaler using inhalation profiles from patients with chronic obstructive pulmonary disease.
Bagherisadeghi G; Chrystyn H; Abadelah M; Larhrib EH
Eur J Pharm Sci; 2019 Nov; 139():105059. PubMed ID: 31472254
[TBL] [Abstract][Full Text] [Related]
11. Real-life association between inhaler technique, patient preference and asthma control in patients with uncontrolled asthma switched to budesonide/formoterol DuoResp® Spiromax® combination.
Roche N; Aguilaniu B; Paternotte S; Dallery N
J Asthma; 2022 Apr; 59(4):765-774. PubMed ID: 33493074
[No Abstract] [Full Text] [Related]
12. Effect of budesonide/formoterol pressurized metered-dose inhaler on exacerbations versus formoterol in chronic obstructive pulmonary disease: The 6-month, randomized RISE (Revealing the Impact of Symbicort in reducing Exacerbations in COPD) study.
Ferguson GT; Tashkin DP; Skärby T; Jorup C; Sandin K; Greenwood M; Pemberton K; Trudo F
Respir Med; 2017 Nov; 132():31-41. PubMed ID: 29229103
[TBL] [Abstract][Full Text] [Related]
13. Narrative Review of the Role of Patient-Reported Outcomes and Inhaler Handling Errors in the Control of Asthma and COPD.
De Simón Gutiérrez R; Castro RP
Curr Allergy Asthma Rep; 2022 Nov; 22(11):151-161. PubMed ID: 36087251
[TBL] [Abstract][Full Text] [Related]
14. Budesonide/formoterol maintenance and reliever therapy in Asian patients (aged ≥16 years) with asthma: a sub-analysis of the COSMOS study.
Vogelmeier C; Naya I; Ekelund J
Clin Drug Investig; 2012 Jul; 32(7):439-49. PubMed ID: 22607479
[TBL] [Abstract][Full Text] [Related]
15. The economic burden of asthma and chronic obstructive pulmonary disease and the impact of poor inhalation technique with commonly prescribed dry powder inhalers in three European countries.
Lewis A; Torvinen S; Dekhuijzen PN; Chrystyn H; Watson AT; Blackney M; Plich A
BMC Health Serv Res; 2016 Jul; 16():251. PubMed ID: 27406133
[TBL] [Abstract][Full Text] [Related]
16. Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial.
Hardy J; Baggott C; Fingleton J; Reddel HK; Hancox RJ; Harwood M; Corin A; Sparks J; Hall D; Sabbagh D; Mane S; Vohlidkova A; Martindale J; Williams M; Shirtcliffe P; Holliday M; Weatherall M; Beasley R;
Lancet; 2019 Sep; 394(10202):919-928. PubMed ID: 31451207
[TBL] [Abstract][Full Text] [Related]
17. A Multicenter, Observational, Prospective Study of the Effectiveness of Switching from Budesonide/Formoterol Turbuhaler
Syk J; Vinge I; Sörberg M; Vahteristo M; Rytilä P
Adv Ther; 2019 Jul; 36(7):1756-1769. PubMed ID: 30941722
[TBL] [Abstract][Full Text] [Related]
18. Combination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and children.
Kew KM; Karner C; Mindus SM; Ferrara G
Cochrane Database Syst Rev; 2013 Dec; (12):CD009019. PubMed ID: 24343671
[TBL] [Abstract][Full Text] [Related]
19. Spiromax, a New Dry Powder Inhaler: Dose Consistency under Simulated Real-World Conditions.
Canonica GW; Arp J; Keegstra JR; Chrystyn H
J Aerosol Med Pulm Drug Deliv; 2015 Oct; 28(5):309-19. PubMed ID: 26352860
[TBL] [Abstract][Full Text] [Related]
20. Effect of inhalation profile and throat geometry on predicted lung deposition of budesonide and formoterol (BF) in COPD: An in-vitro comparison of Spiromax with Turbuhaler.
Chrystyn H; Safioti G; Keegstra JR; Gopalan G
Int J Pharm; 2015 Aug; 491(1-2):268-76. PubMed ID: 26043823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
